ABBOTT LABORATORIES (ABL.DE) Fundamental Analysis & Valuation

FRA:ABL • US0028241000

95.98 EUR
-1.83 (-1.87%)
Last: Mar 5, 2026, 07:00 PM

This ABL.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

ABL gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 63 industry peers in the Health Care Equipment & Supplies industry. ABL scores excellent on profitability, but there are some minor concerns on its financial health. While showing a medium growth rate, ABL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

7

1. ABL.DE Profitability Analysis

1.1 Basic Checks

  • ABL had positive earnings in the past year.
  • ABL had a positive operating cash flow in the past year.
  • ABL had positive earnings in each of the past 5 years.
  • Of the past 5 years ABL 4 years had a positive operating cash flow.
ABL.DE Yearly Net Income VS EBIT VS OCF VS FCFABL.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

1.2 Ratios

  • ABL's Return On Assets of 16.60% is amongst the best of the industry. ABL outperforms 93.65% of its industry peers.
  • ABL has a Return On Equity of 27.43%. This is amongst the best in the industry. ABL outperforms 93.65% of its industry peers.
  • ABL has a better Return On Invested Capital (8.88%) than 74.60% of its industry peers.
Industry RankSector Rank
ROA 16.6%
ROE 27.43%
ROIC 8.88%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ABL.DE Yearly ROA, ROE, ROICABL.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • Looking at the Profit Margin, with a value of 31.88%, ABL belongs to the top of the industry, outperforming 98.41% of the companies in the same industry.
  • In the last couple of years the Profit Margin of ABL has grown nicely.
  • The Operating Margin of ABL (18.29%) is better than 76.19% of its industry peers.
  • In the last couple of years the Operating Margin of ABL has grown nicely.
  • With a Gross Margin value of 56.19%, ABL perfoms like the industry average, outperforming 49.21% of the companies in the same industry.
  • ABL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 18.29%
PM (TTM) 31.88%
GM 56.19%
OM growth 3Y-0.87%
OM growth 5Y4.37%
PM growth 3Y-2.51%
PM growth 5Y2.53%
GM growth 3Y0.26%
GM growth 5Y-0.01%
ABL.DE Yearly Profit, Operating, Gross MarginsABL.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

6

2. ABL.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ABL is destroying value.
  • There is no outstanding debt for ABL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ABL.DE Yearly Shares OutstandingABL.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
ABL.DE Yearly Total Debt VS Total AssetsABL.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

2.2 Solvency

  • An Altman-Z score of 5.38 indicates that ABL is not in any danger for bankruptcy at the moment.
  • ABL has a Altman-Z score of 5.38. This is amongst the best in the industry. ABL outperforms 88.89% of its industry peers.
  • ABL has a debt to FCF ratio of 1.87. This is a very positive value and a sign of high solvency as it would only need 1.87 years to pay back of all of its debts.
  • The Debt to FCF ratio of ABL (1.87) is better than 80.95% of its industry peers.
  • A Debt/Equity ratio of 0.23 indicates that ABL is not too dependend on debt financing.
  • ABL's Debt to Equity ratio of 0.23 is fine compared to the rest of the industry. ABL outperforms 69.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF 1.87
Altman-Z 5.38
ROIC/WACC0.89
WACC9.94%
ABL.DE Yearly LT Debt VS Equity VS FCFABL.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.3 Liquidity

  • ABL has a Current Ratio of 1.70. This is a normal value and indicates that ABL is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.70, ABL perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
  • A Quick Ratio of 1.24 indicates that ABL should not have too much problems paying its short term obligations.
  • The Quick ratio of ABL (1.24) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.24
ABL.DE Yearly Current Assets VS Current LiabilitesABL.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

5

3. ABL.DE Growth Analysis

3.1 Past

  • ABL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.28%, which is quite good.
  • Measured over the past 5 years, ABL shows a small growth in Earnings Per Share. The EPS has been growing by 7.13% on average per year.
  • Looking at the last year, ABL shows a small growth in Revenue. The Revenue has grown by 5.67% in the last year.
  • The Revenue has been growing slightly by 5.08% on average over the past years.
EPS 1Y (TTM)10.28%
EPS 3Y-1.2%
EPS 5Y7.13%
EPS Q2Q%11.94%
Revenue 1Y (TTM)5.67%
Revenue growth 3Y0.51%
Revenue growth 5Y5.08%
Sales Q2Q%4.42%

3.2 Future

  • The Earnings Per Share is expected to grow by 10.38% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 7.06% on average over the next years.
EPS Next Y11.5%
EPS Next 2Y10.76%
EPS Next 3Y10.33%
EPS Next 5Y10.38%
Revenue Next Year7%
Revenue Next 2Y7.19%
Revenue Next 3Y7.11%
Revenue Next 5Y7.06%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ABL.DE Yearly Revenue VS EstimatesABL.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B
ABL.DE Yearly EPS VS EstimatesABL.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8 10

3

4. ABL.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 21.71, ABL is valued on the expensive side.
  • 66.67% of the companies in the same industry are more expensive than ABL, based on the Price/Earnings ratio.
  • ABL is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.74, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 19.47, which indicates a rather expensive current valuation of ABL.
  • The rest of the industry has a similar Price/Forward Earnings ratio as ABL.
  • When comparing the Price/Forward Earnings ratio of ABL to the average of the S&P500 Index (24.82), we can say ABL is valued slightly cheaper.
Industry RankSector Rank
PE 21.71
Fwd PE 19.47
ABL.DE Price Earnings VS Forward Price EarningsABL.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • ABL's Enterprise Value to EBITDA is on the same level as the industry average.
  • ABL's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 28.11
EV/EBITDA 18.21
ABL.DE Per share dataABL.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • ABL has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.89
PEG (5Y)3.05
EPS Next 2Y10.76%
EPS Next 3Y10.33%

5

5. ABL.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 2.17%, ABL has a reasonable but not impressive dividend return.
  • ABL's Dividend Yield is a higher than the industry average which is at 1.06.
  • ABL's Dividend Yield is comparable with the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 2.17%

5.2 History

  • On average, the dividend of ABL grows each year by 11.40%, which is quite nice.
Dividend Growth(5Y)11.4%
Div Incr Years6
Div Non Decr Years6
ABL.DE Yearly Dividends per shareABL.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • ABL pays out 28.93% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of ABL is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP28.93%
EPS Next 2Y10.76%
EPS Next 3Y10.33%
ABL.DE Yearly Income VS Free CF VS DividendABL.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B
ABL.DE Dividend Payout.ABL.DE Dividend Payout, showing the Payout Ratio.ABL.DE Dividend Payout.PayoutRetained Earnings

ABL.DE Fundamentals: All Metrics, Ratios and Statistics

ABBOTT LABORATORIES

FRA:ABL (3/5/2026, 7:00:00 PM)

95.98

-1.83 (-1.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-22
Earnings (Next)04-14
Inst Owners81.33%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap166.90B
Revenue(TTM)44.33B
Net Income(TTM)13.98B
Analysts80
Price Target114.26 (19.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.17%
Yearly Dividend1.88
Dividend Growth(5Y)11.4%
DP28.93%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.82%
Min EPS beat(2)-1.06%
Max EPS beat(2)-0.58%
EPS beat(4)1
Avg EPS beat(4)-0.52%
Min EPS beat(4)-1.16%
Max EPS beat(4)0.73%
EPS beat(8)3
Avg EPS beat(8)0.07%
EPS beat(12)7
Avg EPS beat(12)1.63%
EPS beat(16)11
Avg EPS beat(16)5.69%
Revenue beat(2)0
Avg Revenue beat(2)-0.81%
Min Revenue beat(2)-1.29%
Max Revenue beat(2)-0.33%
Revenue beat(4)0
Avg Revenue beat(4)-1.08%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)-0.33%
Revenue beat(8)0
Avg Revenue beat(8)-0.75%
Revenue beat(12)4
Avg Revenue beat(12)0.15%
Revenue beat(16)8
Avg Revenue beat(16)1.85%
PT rev (1m)-8.74%
PT rev (3m)-9.01%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.04%
EPS NY rev (1m)0.14%
EPS NY rev (3m)0.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)-0.18%
Revenue NY rev (3m)-0.64%
Valuation
Industry RankSector Rank
PE 21.71
Fwd PE 19.47
P/S 4.43
P/FCF 28.11
P/OCF 21.32
P/B 3.82
P/tB 9.09
EV/EBITDA 18.21
EPS(TTM)4.42
EY4.61%
EPS(NY)4.93
Fwd EY5.14%
FCF(TTM)3.41
FCFY3.56%
OCF(TTM)4.5
OCFY4.69%
SpS21.64
BVpS25.15
TBVpS10.56
PEG (NY)1.89
PEG (5Y)3.05
Graham Number50.02
Profitability
Industry RankSector Rank
ROA 16.6%
ROE 27.43%
ROCE 11.52%
ROIC 8.88%
ROICexc 9.99%
ROICexgc 19.14%
OM 18.29%
PM (TTM) 31.88%
GM 56.19%
FCFM 15.78%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-0.87%
OM growth 5Y4.37%
PM growth 3Y-2.51%
PM growth 5Y2.53%
GM growth 3Y0.26%
GM growth 5Y-0.01%
F-Score8
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF 1.87
Debt/EBITDA 1.04
Cap/Depr 70.33%
Cap/Sales 5.02%
Interest Coverage 250
Cash Conversion 81.77%
Profit Quality 49.49%
Current Ratio 1.7
Quick Ratio 1.24
Altman-Z 5.38
F-Score8
WACC9.94%
ROIC/WACC0.89
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.28%
EPS 3Y-1.2%
EPS 5Y7.13%
EPS Q2Q%11.94%
EPS Next Y11.5%
EPS Next 2Y10.76%
EPS Next 3Y10.33%
EPS Next 5Y10.38%
Revenue 1Y (TTM)5.67%
Revenue growth 3Y0.51%
Revenue growth 5Y5.08%
Sales Q2Q%4.42%
Revenue Next Year7%
Revenue Next 2Y7.19%
Revenue Next 3Y7.11%
Revenue Next 5Y7.06%
EBIT growth 1Y15.18%
EBIT growth 3Y-0.36%
EBIT growth 5Y9.67%
EBIT Next Year25.72%
EBIT Next 3Y14.17%
EBIT Next 5Y13.17%
FCF growth 1Y6.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.48%
OCF growth 3YN/A
OCF growth 5YN/A

ABBOTT LABORATORIES / ABL.DE FAQ

What is the fundamental rating for ABL stock?

ChartMill assigns a fundamental rating of 6 / 10 to ABL.DE.


Can you provide the valuation status for ABBOTT LABORATORIES?

ChartMill assigns a valuation rating of 3 / 10 to ABBOTT LABORATORIES (ABL.DE). This can be considered as Overvalued.


What is the profitability of ABL stock?

ABBOTT LABORATORIES (ABL.DE) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for ABL stock?

The Price/Earnings (PE) ratio for ABBOTT LABORATORIES (ABL.DE) is 21.71 and the Price/Book (PB) ratio is 3.82.


How sustainable is the dividend of ABBOTT LABORATORIES (ABL.DE) stock?

The dividend rating of ABBOTT LABORATORIES (ABL.DE) is 5 / 10 and the dividend payout ratio is 28.93%.